Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections
The Centers for Disease Control and Prevention (CDC) characterized carbapenem-resistant Enterobacteriaceae (CRE) as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”.
Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE.
Achaogen is developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens.
Our research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.